Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease

References

• Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3–11.
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol 1995;30:699–706.
   PubMed Web of Science ®Google Scholar
• Levenstein S, Prantera C, Varvo V, Scribano ML, Andreoli A, Luzi C, et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 2000;95:1213–20.
   PubMed Web of Science ®Google Scholar
• Soderholm JD, Yang PC, Ceponis P, Vohra A, Riddell R, Sherman PM, et al. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 2002;123:1099–108.
   PubMed Web of Science ®Google Scholar
• Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with NSAID. Postgrad Med J 1981;57:297–9.
   PubMed Web of Science ®Google Scholar
• Hey H, Schmedes A, Nielsen AA, Winding P, Gronbaek H. Effects of five different alcoholic drinks on patients with Crohn’s disease. Scand J Gastroenterol 2007;42:968–72.
   PubMed Web of Science ®Google Scholar
• Miner PBJr. Factors influencing the relapse of patients with inflammatory bowel disease. Am J Gastroenterol 1997;92:1S–4S.
   PubMed Web of Science ®Google Scholar
• Orchard TR, Thiygaraja S, Welsh KI, Wordsworth BP, Gaston JHS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies in inflammatory bowel disease. Gastroenterology 2000;118:274–8.
   PubMed Web of Science ®Google Scholar
• Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998;42:387–91.
   PubMed Web of Science ®Google Scholar
• Campieri M, Franchi LGA, Bazzocchi G, Brignola C, Benatia B, Boccia S, et al. Prostaglandins, indomethacin and ulcerative colitis. Gastroenterology 1980;78:193.
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastro intestinal safety of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888–99.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Hayllar J, Macpherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 1993;104:1832–47.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
   PubMed Web of Science ®Google Scholar
• Rampton DS, Sladen GE. Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. Prostaglandins 1981;21:417–25.
   PubMed Web of Science ®Google Scholar
• Kaufman HJ, Taubin HL. NSAID activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513–16.
   PubMed Web of Science ®Google Scholar
• Pearson DJ, Stones NA, Bentley SJ. Proctocolitis induced by salicylate and associated with asthma and recurrent nasal polyps. BMJ 1983;287:1675.
   PubMed Web of Science ®Google Scholar
• Walt RP, Hawkey CJ, Langman MJ. Colitis associated with non-steroidal anti-inflammatory drugs. BMJ 1984;288:238.
   PubMed Web of Science ®Google Scholar
• Rutherford D, Stockdill G, Hamer-Hodges DW, Ferguson A. Proctocolitis induced by salicylate. BMJ 1984;288:794.
   PubMed Web of Science ®Google Scholar
• Rampton DS, McNeil MI, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut 1983;24:187–9.
   PubMed Web of Science ®Google Scholar
• Evans JMM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997;40:619–22.
   PubMed Web of Science ®Google Scholar
• Bonner GF, Walczak M, Kitchen L, Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 2000;95:1946–8.
   PubMed Web of Science ®Google Scholar
• Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:751–7.
   PubMed Web of Science ®Google Scholar
• Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000;95:1949–54.
   PubMed Web of Science ®Google Scholar
• Meyer AM, Ramzan NN, Heigh RI, Leighton JA. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 2006;51:168–72.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010;105:1994–2002.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:196–202.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Miehsler W, Dejaco C, Harrer M, Waldhoer T, Lichtenberger C, et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther 2003;17:1371–80.
   PubMed Web of Science ®Google Scholar
• Biancone L, Tosti C, Geremia A, Fina D, Petruzziello C, Emerenziani S, et al. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther 2004;19:755–64.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006;4:203–11.
   PubMed Web of Science ®Google Scholar
• El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006;10:311–17.
   Google Scholar
• Kvasnovsky CL, Papagrigoriadis S, Bjarnason I. Increased diverticular complications with NSAIDs and other medications: a systematic review and meta-analysis. Colorectal Dis 2014;16:O189–96.
   Web of Science ®Google Scholar
• Bjarnason I, Macpherson AJS, Somasundaram S, Teahon K. Non-steroidal anti-inflammatory drugs and Crohn’s disease. In Scholmeric J, Kruis W, Goebbell H, Hohenberger W, Gross V, editors. Inflammatory bowel diseases: pathophysiology as basis of treatment. Falk Symposium No 67. Lancaster: Kluwer Academic Publishers; 1993. pp 208–22.
   Google Scholar
• Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571–607.
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501–23.
   PubMed Web of Science ®Google Scholar
• Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet 2002;359:341–5.
   PubMed Web of Science ®Google Scholar
• Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J 2003;20:54–60.
   PubMed Web of Science ®Google Scholar
• Tibble J, Roseth A, Teahon K, Thjodleifsson B, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000;47:506–13.
   PubMed Web of Science ®Google Scholar
• Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176–80.
   PubMed Web of Science ®Google Scholar